Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2006 1
2015 1
2018 1
2019 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Shiga Toxin-Associated Hemolytic Uremic Syndrome in Adults, France, 2009-2017.
Travert B, Dossier A, Jamme M, Cointe A, Delmas Y, Malot S, Wynckel A, Seguin A, Presne C, Hie M, Benhamou Y, Ribes D, Choukroun G, Grangé S, Hertig A, Le Gall EC, Galicier L, Daugas E, Bouadma L, Weill FX, Azoulay E, Fakhouri F, Veyradier A, Bonacorsi S, Hogan J, Frémeaux-Bacchi V, Rondeau E, Mariani-Kurkdjian P, Coppo P; Centre de Référence des Microangiopathies Thrombotiques2. Travert B, et al. Emerg Infect Dis. 2021;27(7):1876-1885. doi: 10.3201/eid2707.204638. Emerg Infect Dis. 2021. PMID: 34152955 Free PMC article.
We used multivariate analysis to determine that the greatest risk factors for death were underlying immunodeficiency (hazard ratio 3.54) and severe neurologic events (hazard ratio 3.40). According to multivariate analysis and propensity score-matching, eculizumab treatment …
We used multivariate analysis to determine that the greatest risk factors for death were underlying immunodeficiency (hazard ratio 3.54) and …
Is Plasma Exchange Efficacious in Shiga Toxin-Associated Hemolytic Uremic Syndrome? A Narrative Review of Current Evidence.
Keenswijk W, Raes A, De Clerck M, Vande Walle J. Keenswijk W, et al. Ther Apher Dial. 2019 Apr;23(2):118-125. doi: 10.1111/1744-9987.12768. Epub 2018 Nov 19. Ther Apher Dial. 2019. PMID: 30324646 Review.
Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS) is associated with significant mortality and morbidity. ...Outcomes were variable but seemed to point towards lower case fatality rates in the elderly and improved outcomes in ch …
Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS) is associated with significant mortali …
Shiga toxin-associated hemolytic uremic syndrome: absence of recurrence after renal transplantation.
Ferraris JR, Ramirez JA, Ruiz S, Caletti MG, Vallejo G, Piantanida JJ, Araujo JL, Sojo ET. Ferraris JR, et al. Pediatr Nephrol. 2002 Oct;17(10):809-14. doi: 10.1007/s00467-002-0936-9. Epub 2002 Aug 10. Pediatr Nephrol. 2002. PMID: 12376808 Clinical Trial.
We evaluated the relationship between the acute phase and the development of end-stage renal disease (ESRD) and the outcome of renal transplant in patients with Shiga toxin-associated hemolytic uremic syndrome (Stx-HUS). A 20-year retrosp …
We evaluated the relationship between the acute phase and the development of end-stage renal disease (ESRD) and the outcome of renal transpl …
Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background.
Bresin E, Daina E, Noris M, Castelletti F, Stefanov R, Hill P, Goodship TH, Remuzzi G; International Registry of Recurrent and Familial HUS/TTP. Bresin E, et al. Clin J Am Soc Nephrol. 2006 Jan;1(1):88-99. doi: 10.2215/CJN.00050505. Epub 2005 Nov 2. Clin J Am Soc Nephrol. 2006. PMID: 17699195 Review.
More than 50% of patients with non-Shiga toxin-associated hemolytic uremic syndrome (non-Stx-HUS) progress to ESRD. ...Patients with non-Stx-HUS should undergo genotyping before renal transplantation to help predict the risk for gr …
More than 50% of patients with non-Shiga toxin-associated hemolytic uremic syndrome (non-Stx-HUS) …
The efficacy of recombinant human soluble thrombomodulin for the treatment of shiga toxin-associated hemolytic uremic syndrome model mice.
Suyama K, Kawasaki Y, Miyazaki K, Kanno S, Ono A, Ohara S, Sato M, Hosoya M. Suyama K, et al. Nephrol Dial Transplant. 2015 Jun;30(6):969-77. doi: 10.1093/ndt/gfv004. Epub 2015 Feb 17. Nephrol Dial Transplant. 2015. PMID: 25694534
Loss of body weight, serum creatinine level, endothelial injury and mesangiolysis scores at 24 h after administration in the t-HUS mice treated with rhTM were lower than those in t-HUS mice treated with saline. ...
Loss of body weight, serum creatinine level, endothelial injury and mesangiolysis scores at 24 h after administration in the t-HUS mi …